A soft tissue diagnosis in a performance horse almost always leads to a conversation about regenerative therapies. Platelet-rich plasma, stem cell treatment, and shockwave therapy are now standard offerings at equine referral practices and are increasingly available through ambulatory veterinarians. Owners navigating these options frequently encounter confident claims alongside limited explanation of what each therapy actually does and what the evidence supporting it looks like.
This post does not recommend one therapy over another. It explains the mechanism behind each, what the research shows about outcomes, and how these treatments fit into a broader rehabilitation program.
Why Regenerative Therapies Exist
The challenge with tendon and ligament injuries is not that the body cannot repair them. It is that the repair process is slow, produces tissue that is not identical to the original, and carries a high rate of incomplete or disorganized healing that leaves horses vulnerable to reinjury.
Regenerative therapies attempt to improve on that biological baseline by enhancing the signaling environment at the injury site, accelerating certain phases of repair, or introducing cellular components that support more organized tissue formation. The goal is not to replace the natural healing process but to influence it toward better outcomes.
Platelet-Rich Plasma
Platelet-rich plasma, commonly called PRP, is produced by drawing a sample of the horse's own blood, centrifuging it to concentrate the platelet fraction, and injecting the resulting preparation into or around the injury site.
Platelets contain growth factors, signaling proteins that play a role in initiating and regulating the repair process. By concentrating platelets at the injury site, PRP aims to amplify the biological signals that drive tissue repair and may influence the quality of collagen deposition during the proliferative phase of healing.
The research on PRP in equine tendon and ligament injuries shows mixed but generally promising results for certain injury types. Studies on SDFT injuries have found improvements in ultrasonographic appearance and fiber organization in PRP-treated horses compared to controls, though long-term performance outcomes vary across studies. PRP is relatively accessible, involves minimal processing compared to stem cell therapies, and uses the horse's own biological material, limiting immune reaction risk.
PRP preparations vary considerably in platelet concentration and growth factor content depending on the processing system used. Not all PRP is equivalent, which partly explains variability in reported outcomes.
Stem Cell Therapy
Stem cell therapies for equine soft tissue injuries typically use mesenchymal stem cells, cells capable of differentiating into connective tissue types including those relevant to tendon and ligament repair. Two primary sources are used in practice: bone marrow aspirate and adipose tissue, each requiring collection from the horse and, in some protocols, laboratory processing and culture expansion before injection.
The proposed mechanism is that stem cells introduced into the injury site differentiate into tenocyte-like cells, secrete growth factors that modulate the repair environment, and reduce the formation of disorganized scar tissue during healing. The goal is more organized collagen deposition and reduced fibrosis within the repair zone.
Clinical studies on stem cell therapy in SDFT injuries have shown improvements in lesion fill and fiber organization on imaging, and some long-term follow-up data suggests reduced reinjury rates compared to conventional management in certain populations. The evidence base is still developing, and results vary depending on cell source, processing method, timing of treatment, and injury characteristics.
Stem cell therapy is more expensive and logistically complex than PRP, particularly protocols requiring laboratory culture expansion. Timing is also a consideration: some protocols require a gap between injury and treatment that must be planned in advance.
Shockwave Therapy
Extracorporeal shockwave therapy delivers high-energy acoustic waves to a targeted tissue area using an applicator pressed against the skin surface. Unlike PRP and stem cell treatments, shockwave does not introduce biological material. It works through mechanical and biological effects generated by the acoustic energy itself.
In soft tissue injuries, shockwave is thought to stimulate cellular activity within the repair zone, increase local blood flow, and influence the signaling environment in ways that support tissue remodeling. It has also demonstrated analgesic effects, reducing pain signaling from the treated area. This latter effect is relevant to management decisions because pain reduction can improve a horse's willingness to load the limb during controlled rehabilitation, but it also means that a horse treated with shockwave may feel more comfortable than its tissue healing would otherwise support.
Shockwave is used most commonly for proximal suspensory desmitis, where its ability to stimulate remodeling in a confined, poorly vascularized area is particularly relevant. It is typically applied in a series of treatments spaced weeks apart and is often used alongside other therapies rather than as a standalone treatment.
Its analgesic effect has competition withdrawal implications in some regulatory contexts, which is relevant for horses in active competition programs.
How These Therapies Fit Into Rehabilitation
None of these therapies replaces structured rehabilitation. PRP injected into an SDFT lesion does not eliminate the need for controlled exercise progression, serial imaging, and patient return-to-work management. Stem cells introduced into a suspensory injury do not accelerate the timeline to the point where normal rehabilitation phases can be skipped. Shockwave applied to a proximal suspensory origin does not substitute for the controlled loading that guides fiber alignment during remodeling.
What these therapies aim to do is improve the biological quality of the repair process that structured rehabilitation is already directing. They are additions to a comprehensive program, not replacements for its foundational components.
Timing of treatment relative to injury phase matters for all three. PRP and stem cell therapies are generally most relevant during the proliferative phase of healing, after the acute inflammatory response has subsided. Shockwave timing varies by protocol and injury type. Veterinary guidance on which therapy is appropriate, when, and how it integrates with the rehabilitation program is essential.
Supporting the Biological Environment Throughout
Regenerative therapies address specific phases of the repair process. Supporting the broader biological environment in which tendon and ligament healing occurs is relevant throughout rehabilitation and beyond.
Tendonall is formulated to support tendon and ligament biology and is commonly used alongside veterinary-guided rehabilitation programs, including those incorporating regenerative therapies, to provide consistent nutritional support for collagen synthesis and connective tissue remodeling across the full recovery timeline.
Regenerative therapies represent a genuine advance in equine soft tissue management. Understanding what each one does, what the evidence supports, and how they fit into a complete rehabilitation program allows owners to engage with these options from an informed position rather than a marketing one.
PRP, Stem Cells, and Shockwave: What Regenerative Therapies Actually Do for Horse Tendon and Ligament Injuries
A soft tissue diagnosis in a performance horse almost always leads to a conversation about regenerative therapies. Platelet-rich plasma, stem cell treatment, and shockwave therapy are now standard offerings at equine referral practices and are increasingly available through ambulatory veterinarians. Owners navigating these options frequently encounter confident claims alongside limited explanation of what each therapy actually does and what the evidence supporting it looks like.
This post does not recommend one therapy over another. It explains the mechanism behind each, what the research shows about outcomes, and how these treatments fit into a broader rehabilitation program.
Why Regenerative Therapies Exist
The challenge with tendon and ligament injuries is not that the body cannot repair them. It is that the repair process is slow, produces tissue that is not identical to the original, and carries a high rate of incomplete or disorganized healing that leaves horses vulnerable to reinjury.
Regenerative therapies attempt to improve on that biological baseline by enhancing the signaling environment at the injury site, accelerating certain phases of repair, or introducing cellular components that support more organized tissue formation. The goal is not to replace the natural healing process but to influence it toward better outcomes.
Platelet-Rich Plasma
Platelet-rich plasma, commonly called PRP, is produced by drawing a sample of the horse's own blood, centrifuging it to concentrate the platelet fraction, and injecting the resulting preparation into or around the injury site.
Platelets contain growth factors, signaling proteins that play a role in initiating and regulating the repair process. By concentrating platelets at the injury site, PRP aims to amplify the biological signals that drive tissue repair and may influence the quality of collagen deposition during the proliferative phase of healing.
The research on PRP in equine tendon and ligament injuries shows mixed but generally promising results for certain injury types. Studies on SDFT injuries have found improvements in ultrasonographic appearance and fiber organization in PRP-treated horses compared to controls, though long-term performance outcomes vary across studies. PRP is relatively accessible, involves minimal processing compared to stem cell therapies, and uses the horse's own biological material, limiting immune reaction risk.
PRP preparations vary considerably in platelet concentration and growth factor content depending on the processing system used. Not all PRP is equivalent, which partly explains variability in reported outcomes.
Stem Cell Therapy
Stem cell therapies for equine soft tissue injuries typically use mesenchymal stem cells, cells capable of differentiating into connective tissue types including those relevant to tendon and ligament repair. Two primary sources are used in practice: bone marrow aspirate and adipose tissue, each requiring collection from the horse and, in some protocols, laboratory processing and culture expansion before injection.
The proposed mechanism is that stem cells introduced into the injury site differentiate into tenocyte-like cells, secrete growth factors that modulate the repair environment, and reduce the formation of disorganized scar tissue during healing. The goal is more organized collagen deposition and reduced fibrosis within the repair zone.
Clinical studies on stem cell therapy in SDFT injuries have shown improvements in lesion fill and fiber organization on imaging, and some long-term follow-up data suggests reduced reinjury rates compared to conventional management in certain populations. The evidence base is still developing, and results vary depending on cell source, processing method, timing of treatment, and injury characteristics.
Stem cell therapy is more expensive and logistically complex than PRP, particularly protocols requiring laboratory culture expansion. Timing is also a consideration: some protocols require a gap between injury and treatment that must be planned in advance.
Shockwave Therapy
Extracorporeal shockwave therapy delivers high-energy acoustic waves to a targeted tissue area using an applicator pressed against the skin surface. Unlike PRP and stem cell treatments, shockwave does not introduce biological material. It works through mechanical and biological effects generated by the acoustic energy itself.
In soft tissue injuries, shockwave is thought to stimulate cellular activity within the repair zone, increase local blood flow, and influence the signaling environment in ways that support tissue remodeling. It has also demonstrated analgesic effects, reducing pain signaling from the treated area. This latter effect is relevant to management decisions because pain reduction can improve a horse's willingness to load the limb during controlled rehabilitation, but it also means that a horse treated with shockwave may feel more comfortable than its tissue healing would otherwise support.
Shockwave is used most commonly for proximal suspensory desmitis, where its ability to stimulate remodeling in a confined, poorly vascularized area is particularly relevant. It is typically applied in a series of treatments spaced weeks apart and is often used alongside other therapies rather than as a standalone treatment.
Its analgesic effect has competition withdrawal implications in some regulatory contexts, which is relevant for horses in active competition programs.
How These Therapies Fit Into Rehabilitation
None of these therapies replaces structured rehabilitation. PRP injected into an SDFT lesion does not eliminate the need for controlled exercise progression, serial imaging, and patient return-to-work management. Stem cells introduced into a suspensory injury do not accelerate the timeline to the point where normal rehabilitation phases can be skipped. Shockwave applied to a proximal suspensory origin does not substitute for the controlled loading that guides fiber alignment during remodeling.
What these therapies aim to do is improve the biological quality of the repair process that structured rehabilitation is already directing. They are additions to a comprehensive program, not replacements for its foundational components.
Timing of treatment relative to injury phase matters for all three. PRP and stem cell therapies are generally most relevant during the proliferative phase of healing, after the acute inflammatory response has subsided. Shockwave timing varies by protocol and injury type. Veterinary guidance on which therapy is appropriate, when, and how it integrates with the rehabilitation program is essential.
Supporting the Biological Environment Throughout
Regenerative therapies address specific phases of the repair process. Supporting the broader biological environment in which tendon and ligament healing occurs is relevant throughout rehabilitation and beyond.
Tendonall is formulated to support tendon and ligament biology and is commonly used alongside veterinary-guided rehabilitation programs, including those incorporating regenerative therapies, to provide consistent nutritional support for collagen synthesis and connective tissue remodeling across the full recovery timeline.
Regenerative therapies represent a genuine advance in equine soft tissue management. Understanding what each one does, what the evidence supports, and how they fit into a complete rehabilitation program allows owners to engage with these options from an informed position rather than a marketing one.